Aspreva cuts a quarter of its jobs as it refocuses - FierceBiotech - Biotechnology Articles, Biotech Industry News, FDA Approval News

Aspreva cuts a quarter of its jobs as it refocuses - FierceBiotech - Biotechnology Articles, Biotech Industry News, FDA Approval News: "Canada's Aspreva Pharmaceuticals says that Chief Scientific Officer Richard Jones is leaving the company as the biotech cuts 33 jobs, or about a quarter of its work force. Company officials say they want to concentrate on their core functions. Aspreva recently completed a late-stage trial for an experimental therapy for myasthenia gravis and another trial for a treatment of lupus nephritis. Aspreva says it remains committed to a pact it has with Roche."